BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Sparsentan is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline for adults with primary IgA nephropathy who are at risk for disease progression.

"Shoppers will start seeing it at scale across the store in the next 90 days," John Ross, the CEO of Chicago-heaquartered IGA, a chain of franchised grocery stores, told CNN. There are over 1,600 ...

The IGA requires Windsor to share some of its wastewater-storage capacity with Greeley, an agreement that Greeley claims has been breached. GREELEY — The Greeley City Council voted unanimously Tuesday ...

Merida is also working on a treatment for a chronic inflammatory kidney disease called primary membranous nephropathy. “At the heart of Merida is understanding the mechanisms behind antibody ...

“Today’s approval marks an important milestone for people living with IgA nephropathy, offering a new option that can be seamlessly integrated into their existing treatment plan, with no REMS ...

IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, according to an announcement by Novartis.

Columbia University Irving Medical Center invites you to join the leading educators from Columbia University, addressing an overview of high yield challenging scenarios in the management of IgA ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat patients with the rare kidney disease immunoglobulin A nephropathy ...

The eGFR data are expected in 2026 and intended to support traditional FDA approval. "The approval marks an important milestone for people living with IgA nephropathy, offering a new option that can ...